Bei Akademie registrieren
Sanofi S.A., FR0000120578

Sanofi stock gains 2.78% since latest report as targets rise

Published on 11/10/2026 at 18:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi's latest report covered stronger analyst views after the upgraded 2026 outlook. Investors still weigh growth beyond Dupixent.

Sanofi outlook and market focus

  • Recent analyst revisions added support to Sanofi's valuation discussion.
  • The upgraded 2026 outlook keeps Dupixent and newer medicines central to the investment case.
  • Investors continue to assess growth prospects beyond Dupixent's period of market exclusivity.
Sanofi S.A., FR0000120578, Illustration mit AI erstellt.
Sanofi S.A., FR0000120578, Illustration mit AI erstellt.

Sanofi stock traded at 86.14 euros on Lang & Schwarz at 18:00 CET on Tuesday, November 10, 2026. That was 2.78% above the 83.81-euro level reported on November 6, giving the latest report a clear market-price update.

Analyst support meets execution questions

The latest Sanofi coverage highlighted a more constructive broker view after the French drugmaker raised its 2026 outlook. Exane BNP Paribas upgraded the shares to Outperform and lifted its target to 102 euros, while UBS retained a Hold rating and raised its target to 88 euros, according to AD HOC NEWS.

The differing ratings point to a split investor assessment. Higher targets support the valuation case, but they remain analyst estimates rather than company guidance. The central question is whether Sanofi can extend its growth profile as investors look beyond Dupixent's current contribution.

What investors watch next

Sanofi's stronger third-quarter performance and higher 2026 outlook have kept Dupixent and newer medicines at the center of the investment case. Pipeline renewal and the sustainability of growth beyond Dupixent's period of market exclusivity remain important for the longer-term equity story.

Sanofi stock at a glance

  • Company: Sanofi S.A.
  • ISIN: FR0000120578
  • Trading venue: Lang & Schwarz
  • Price: 86.14 euros at 18:00 CET on November 10, 2026
  • Change since November 6 report: 2.78% higher than 83.81 euros

Broader pharmaceutical-sector developments remain relevant for Sanofi investors. See the latest Current market reports.

More news and analyses are available on More news and analyses on Sanofi stock.

Disclaimer...
en | FR0000120578 | SANOFI S.A. | boerse | 70487728 | bgmi